Presence & RecognitionEvent: September 2, 2026
Nephrogen is hosting a webinar with partner MilliporeSigma next week to discuss work together in process development for AAV production.
Published
Signal category
Presence & Recognition
Quote
“Excited to join our partner, MilliporeSigma, for a webinar next week to discuss our work together in process development for AAV production.”
— Demetri M.|Nephrogen team
Company
Nephrogen
Curative genetic medicines for kidney and pancreatic diseases
- Industry
- Biotechnology Research
- Location
- New York, US
- Company size
- 6 employees
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas.
Founded 2022